Clinical & Scientific

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

A new clinical trial for a twice-yearly COPD injection could disrupt a multi-billion dollar market, offering hope to millions and validating a novel biotech strategy.

Fredonia Mining advances its flagship gold project while consolidating a key Argentine district, a bold strategy to build a regional powerhouse next to giants.

Promising early data for obesity drug DA-1726 shows rapid weight loss, while vanoglipel demonstrates powerful synergy in MASH and diabetes combination therapies.

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

A breakthrough biomarker, DNlite™, analyzes landmark trial data, offering a new way to identify high-risk diabetes patients missed by current standards.

Visionary Copper and Gold Mines accelerates its Pt. Leamington project, fueled by a major discovery and an ambitious regional strategy in a historic district.

A new study reveals treating advanced gum disease has up to 10x the environmental impact of prevention, reframing sustainability from recycling to daily habits.

With record device sales providing a solid financial base, RenovoRx nears a critical milestone in its high-stakes Phase III trial for a new pancreatic cancer therapy.

A key regulatory win in Japan propels a potential first-ever treatment for Netherton Syndrome, but the real story is the high-wire act of global commercialization.

With its first product launch, Daré Bioscience enters a new commercial era. But can a single probiotic launch secure the future of its ambitious pipeline?

A first-in-class drug aims to calm overactive immune cells, offering a new blueprint for treating diseases like rheumatoid arthritis. But can it deliver?

Jade Biosciences secures a massive $150M offering to fuel its promising drug pipeline, but the deal's pricing reveals the intense pressures of the biotech market.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

A new partnership uses healthcare data expertise to guide military caregivers through a mental health crisis. But is this innovative solution enough?

DNV verifies Carbon Ridge’s compact OCCS hits 98% CO2 capture, offering shipowners a viable path to decarbonize existing fleets without major overhauls.

Precision Cardiovascular adds serial entrepreneur Brian Fahey to its board, signaling a push to commercialize its implantable SAW sensor and AI platform.

As the world grapples with drug-resistant bacteria, an Israeli biotech is testing a novel drug that physically destroys pathogens. Can it turn the tide?

Stonegate Capital's updated coverage validates AB Science's pivot to ALS and AML, but can its promising clinical assets and shrewd financing de-risk the path forward?